ADL Amdl,

TUSTIN, Calif. and TAIPEI, Taiwan, Jan. 31 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, today announced that it has signed a Memorandum of Understanding (MOU) with Vectorite Biomedica, Inc., a Taiwan based company, that could lead to the development of human and animal clinical trials in Taiwan of AMDL's Combination Immunogene Therapy (CIT), a therapeutic vaccine. "Vectorite introduced AMDL, and its CIT technology, to various senior officials from the Chang Gung Memorial Hospital and the National Taiwan University School of Veterinary Medicine, and each has a significant interest in immediately beginning a clinical trial process, potentially including a fast-track Taiwan Food and Drug Administration approval of CIT," said Gary L. Dreher, CEO of AMDL. CIT uses two genes in combination to both build the body's immune system and to destroy cancer cells. Its GM-CSF gene alters the tumor by activating tumor-specific T-cells within the immune system, while its B7-2 gene enters the tumor to stimulate stronger and larger T-cells to attack the cancer. The approach is potentially superior to traditional gene therapy, which seeks to replace damaged or abnormal genes with healthy ones. This has proven to be difficult because of the number of genes involved. CIT was shown to be 100 percent effective in a humanized mouse model in previous clinical trials in Canada. AMDL also said that CIT is synergistic to its DR-70(R) cancer test, giving the Company both the ability to monitor and treat cancers. AMDL's primary objective remains receiving U.S. Food & Drug Administration clearance to market the DR-70(R), which would simultaneously increase market awareness and acceptance in the international marketplace. About Vectorite Biomedica Vectorite Biomedica, a Taiwan-based Company, is devoted to improving the quality of life by applying innovative biotechnology solutions to human diseases. The platform technology of Vectorite includes innovative genetic tools for gene transfer, discovery functional genomics, deciphering disease pathways and drug validation. "We are very much looking forward to taking the next steps necessary in this Memorandum of Understanding, including developing a clinical trial protocol for both studies," said Eddie Ting, President, Vectorite Biomedica, Inc. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a Combination Immunogene Therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements We intend that the statements in this press release that are not historical constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 of the Securities Exchange Act of 1934, as amended and are subject to numerous risks and uncertainties, including the risks (i) that the transaction described may not be completed when expected, or at all, (ii) the risk that the terms of the definitive acquisition agreements may materially differ from that disclosed herein, (iii) the risks related to the inability to obtain or meet conditions imposed for, governmental and other approvals of the transaction, including the approval by the stockholders of AMDL, (iv) risks related to the uncertainty surrounding the transaction and transactions of this type and (v) the costs related thereto. In addition, these forward-looking statements are subject to the other risks of AMDL's business, including, but not limited to, (a) AMDL's failure to complete successfully the development of new or enhanced products, (b) AMDL's future capital needs, (c) the lack of market demand for any new or enhanced products that AMDL may develop, (d) the lack of market acceptance of AMDL's products and its limited revenues to date, (e) the success of competitive products, other economic factors affecting AMDL and its markets, and (f) other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release in the event of new circumstances or unanticipated events that may occur in the future. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright